Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories.
Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories.
复制标题
DOI：
10.2174/1570159x13666150121230133
复制
发表时间：
2016
影响因子：
5.3
通讯作者：
Lud Cadet J
中科院分区：
文献类型：
--
作者：
Lud Cadet J
物质使用障碍是具有实质性负面生物心理社会影响的神经精神疾病。这些疾病被定义为强迫性滥用合法或非法物质，尽管有不利的法医学后果。虽然已经进行了大量的研究，以阐明这些疾病的病理生物学基础，还有很多工作要做，以发展一个总体的神经生物学的理解，可能是有益的药理学治疗。表观遗传学的最新进展有望阐明这一点。在这里，我提供了一个简短的概述，观察使用一些模型的精神兴奋剂管理啮齿动物。审查确定CREB结合蛋白（CBP），HDAC 1，HDAC 2，HADC 3，HDAC 4和HDAC 5作为重要的球员在乙酰化和脱乙酰化过程中发生后，特遣队或非特遣队管理的精神兴奋剂。这些观察结果进行了讨论的框架内，需要更好的成瘾动物模型，以使这些表观遗传学的进步，以承担人类成瘾者的药物治疗。
Substance use disorders are neuropsychiatric illnesses that have substantial negative biopsychosocial impact. These diseases are defined as compulsive abuse of licit or illicit substances despite adverse medicolegal consequences. Although much research has been conducted to elucidate the pathobiological bases of these disorders, much remains to be done to develop an overarching neurobiological understanding that might be translatable to beneficial pharmacological therapies. Recent advances in epigenetics promise to lead to such an elucidation. Here I provide a brief overview of observations obtained using some models of psychostimulant administration in rodents. The review identifies CREB binding protein (CBP), HDAC1, HDAC2, HADC3, HDAC4, and HDAC5 as important players in the acetylation and deacetylation processes that occur after contingent or non-contingent administration of psychostimulants. These observations are discussed within a framework that suggests a need for better animal models of addiction in order to bring these epigenetic advances to bear on the pharmacological treatment of human addicts.